Update on the management of pancreatic cancer:Surgery is not enough

• Published in: World journal of gastroenterology : WJG Vol. 21; no. 11; pp. 3157 - 3165
• Main Authors: Ansari, Daniel, Gustafsson, Adam, Andersson, Roland
• Format: Journal Article
• Language: English
• Published: United States Baishideng Publishing Group Inc 21.03.2015
• Subjects: Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers, Tumor - blood; Biomarkers, Tumor - genetics; cancer;Diagnosis;Genetics;Epigenetics;P; Carcinoma, Pancreatic Ductal - blood; Carcinoma, Pancreatic Ductal - genetics; Carcinoma, Pancreatic Ductal - pathology; Carcinoma, Pancreatic Ductal - surgery; Carcinoma, Pancreatic Ductal - therapy; Chemotherapy, Adjuvant; Clinical Medicine; Early Detection of Cancer; Gastroenterologi; Gastroenterologi och hepatologi; Gastroenterology and Hepatology; Humans; Klinisk medicin; Medical and Health Sciences; Medicin och hälsovetenskap; Molecular Targeted Therapy; Neoadjuvant Therapy - adverse effects; Neoadjuvant Therapy - methods; Neoplasm Recurrence, Local; Neoplasm, Residual; Pancreatectomy - adverse effects; Pancreatic; Pancreatic Neoplasms - blood; Pancreatic Neoplasms - genetics; Pancreatic Neoplasms - mortality; Pancreatic Neoplasms - pathology; Pancreatic Neoplasms - surgery; Pancreatic Neoplasms - therapy; Patient Selection; Precision Medicine; Predictive Value of Tests; Risk Factors; Time Factors; Treatment Outcome; Chemotherapy; Pancreatic cancer; Surgery; Proteomics; Epigenetics; Stroma; Genetics; Diagnosis; Prognostic models
• ISSN: 1007-9327; 2219-2840; 2219-2840
• DOI: 10.3748/wjg.v21.i11.3157

Pancreatic ductal adenocarcinoma(PDAC) represents the fourth cause of death in cancer and has a 5-year survival of < 5%.Only about 15% of the patients present with a resectable PDAC with potential to undergo "curative" surgery.After surgery,local and systemic recurrence,is t...